Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (1463)	2/3/2002 5:21:55 PM
From: tnsaf	Read Replies (1) \| Respond to of 7143

Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery W. Asavaroengchai,, Y. Kotera, and J. J. Mulé,§,¶ Departments of Pathology, Surgery, and § Internal Medicine, University of Michigan Medical Center, 1520 MSRB-I, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0666 Proc. Natl. Acad. Sci. USA, Vol. 99, Issue 2, 931-936, January 22, 2002 Dendritic cells (DC) can serve to immunize the newborn immune system to foreign antigen. In a lymphopenic environment, naive T cells undergoing homeostasis-driven proliferation can acquire increased sensitivity to antigen stimulation. Here, we evaluated the capacity of DC to effectively prime the host immune system to elicit antitumor effects in the setting of early lymphoid reconstitution after bone marrow transplantation (BMT). Indeed, bone marrow-derived, cytokine-driven DC pulsed with whole tumor lysates (TP-DC) could, early on, prime a specific and long-lasting antitumor immune response, which mediated the rejection of a lethal challenge of a weakly immunogenic breast tumor. In the therapeutic setting, TP-DC could also inhibit the growth of preexisting breast tumor metastases by repetitive immunizations initiated early after BMT. Spleen T cells obtained from mice immunized with TP-DC early after BMT showed a substantial increase in tumor-specific IFN- production. Our findings demonstrate that it is possible to promote effective antitumor immunity in a defined lymphopenic environment through DC-based immunization. ------------------------------------------------------------ Present address: Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114-2698. www.pnas.org/cgi/doi/10.1073/pnas.022634999